Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07257876 in Advanced or Metastatic Tumors
NCT04881045Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2021
- Primary completion
- Oct 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of PF-07257876 in non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (HNSCC) and ovarian cancer (3 arms), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicities, Adverse Events and 2 more. Started Aug 2021; status: completed.
02
Drugs
PF-07257876
03
Conditions
non-small cell lung cancer (NSCLC)squamous cell carcinoma of the head and neck (HNSCC)ovarian cancer
Beyond the preview
Go deeper on NCT04881045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04881045.